This Study Will Evaluate the Safety, Tolerability, and Efficacy of ANB032 in Subjects with Moderate to Severe Atopic Dermatitis (AD).
Trial details
- Registry ID
- NCT05935085
- Phase
- Phase 2
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| This Study Will Evaluate the Safety, Tolerability, and Efficacy of ANB032 in Subjects with Moderate to Severe Atopic Dermatitis (AD).NCT05935085 | ANAB | Phase 2 | Terminated | 2024-10-16Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |